Karyopharm Therapeutics Inc. Investing Cash Flow
Karyopharm Therapeutics Inc. (KPTI) reported Investing Cash Flow of -$6.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$10.04M, a 154.89% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $3.20M, a 79.07% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $5.00M, a 66.21% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $4.80M, a 35.71% decline year-over-year.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2025 was $43.38M, a 54.57% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2024 was $95.47M, a 1102.43% increase from fiscal 2023.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2023 was $7.94M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$104.26M, a 173.50% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$6.84M 10-Q · filed 2026-08-13 | -$1.84M derived: sum of 3 quarters · filed 2026-08-13 | $2.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.20M 10-Q · filed 2026-05-14 | $8.20M derived: sum of 2 quarters · filed 2026-05-14 | $13.01M derived: sum of 3 quarters · filed 2026-05-14 | $31.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $9.80M derived: sum of 2 quarters · filed 2026-02-13 | $28.09M derived: sum of 3 quarters · filed 2026-08-13 | $43.38M 10-K · filed 2026-02-13 |
| 2025-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $23.09M derived: sum of 2 quarters · filed 2026-08-13 | $38.38M 10-Q · filed 2025-11-03 | $53.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $18.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $33.57M 10-Q · filed 2026-08-13 | $48.37M derived: sum of 3 quarters · filed 2026-08-13 | $55.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $15.29M 10-Q · filed 2026-05-14 | $30.09M derived: sum of 2 quarters · filed 2026-05-14 | $37.56M derived: sum of 3 quarters · filed 2026-05-14 | $88.82M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $22.27M derived: sum of 2 quarters · filed 2026-02-13 | $73.53M derived: sum of 3 quarters · filed 2026-02-13 | $95.47M 10-K · filed 2026-02-13 |
| 2024-09-30 | $7.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $58.74M derived: sum of 2 quarters · filed 2025-11-03 | $80.68M 10-Q · filed 2025-11-03 | $107.52M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | $51.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $73.20M 10-Q · filed 2025-08-11 | $100.05M derived: sum of 3 quarters · filed 2026-02-13 | $92.36M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | $21.94M 10-Q · filed 2025-05-12 | $48.78M derived: sum of 2 quarters · filed 2026-02-13 | $41.10M derived: sum of 3 quarters · filed 2026-02-13 | $62.27M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $26.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $19.16M derived: sum of 2 quarters · filed 2026-02-13 | $40.33M derived: sum of 3 quarters · filed 2026-02-13 | $7.94M 10-K · filed 2026-02-13 |
| 2023-09-30 | -$7.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $13.48M derived: sum of 2 quarters · filed 2024-11-05 | -$18.90M 10-Q · filed 2024-11-05 | -$84.20M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $21.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$11.22M 10-Q · filed 2024-08-06 | -$76.52M derived: sum of 3 quarters · filed 2025-02-19 | -$64.84M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$32.39M 10-Q · filed 2024-05-08 | -$97.69M derived: sum of 2 quarters · filed 2025-02-19 | -$86.01M derived: sum of 3 quarters · filed 2025-02-19 | -$122.61M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$65.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$53.63M derived: sum of 2 quarters · filed 2025-02-19 | -$90.22M derived: sum of 3 quarters · filed 2025-02-19 | -$104.26M 10-K · filed 2025-02-19 |
| 2022-09-30 | $11.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$24.92M derived: sum of 2 quarters · filed 2023-11-02 | -$38.96M 10-Q · filed 2023-11-02 | -$8.19M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$36.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$50.63M 10-Q · filed 2023-08-02 | -$19.86M derived: sum of 3 quarters · filed 2024-02-29 | $1.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$14.04M 10-Q · filed 2023-05-04 | $16.73M derived: sum of 2 quarters · filed 2024-02-29 | $38.16M derived: sum of 3 quarters · filed 2024-02-29 | $84.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $30.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $52.20M derived: sum of 2 quarters · filed 2024-02-29 | $98.65M derived: sum of 3 quarters · filed 2024-02-29 | $141.84M 10-K · filed 2024-02-29 |
| 2021-09-30 | $21.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $67.88M derived: sum of 2 quarters · filed 2022-11-03 | $111.07M 10-Q · filed 2022-11-03 | $142.47M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $46.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $89.64M 10-Q · filed 2022-08-04 | $121.04M derived: sum of 3 quarters · filed 2023-02-17 | $142.47M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $43.19M 10-Q · filed 2022-05-05 | $74.58M derived: sum of 2 quarters · filed 2023-02-17 | $96.01M derived: sum of 3 quarters · filed 2023-02-17 | $35.98M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $31.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $52.83M derived: sum of 2 quarters · filed 2023-02-17 | -$7.21M derived: sum of 3 quarters · filed 2023-02-17 | -$53.69M 10-K · filed 2023-02-17 |
| 2020-09-30 | $21.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$38.60M derived: sum of 2 quarters · filed 2021-11-03 | -$85.08M 10-Q · filed 2021-11-03 | -$118.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$60.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$106.51M 10-Q · filed 2021-08-05 | -$140.03M derived: sum of 3 quarters · filed 2022-03-01 | -$99.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$46.48M 10-Q · filed 2021-05-04 | -$80.00M derived: sum of 2 quarters · filed 2022-03-01 | -$39.82M derived: sum of 3 quarters · filed 2022-03-01 | -$20.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$33.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.66M derived: sum of 2 quarters · filed 2022-03-01 | $46.46M derived: sum of 3 quarters · filed 2022-03-01 | $78.45M 10-K · filed 2022-03-01 |
| 2019-09-30 | $40.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $79.98M derived: sum of 2 quarters · filed 2020-11-02 | $111.97M 10-Q · filed 2020-11-02 | $8.86M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $39.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $71.79M 10-Q · filed 2020-08-04 | -$31.32M derived: sum of 3 quarters · filed 2021-02-24 | -$10.75M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $31.99M 10-Q · filed 2020-05-05 | -$71.12M derived: sum of 2 quarters · filed 2021-02-24 | -$50.55M derived: sum of 3 quarters · filed 2021-02-24 | -$78.16M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$103.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$82.54M derived: sum of 2 quarters · filed 2021-02-24 | -$110.15M derived: sum of 3 quarters · filed 2021-02-24 | -$107.66M 10-K · filed 2021-02-24 |
| 2018-09-30 | $20.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$7.04M derived: sum of 2 quarters · filed 2019-11-04 | -$4.55M 10-Q · filed 2019-11-04 | -$7.46M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$27.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$25.12M 10-Q · filed 2019-08-07 | -$28.02M derived: sum of 3 quarters · filed 2020-02-26 | -$7.43M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $2.48M 10-Q · filed 2019-05-09 | -$417.00K derived: sum of 2 quarters · filed 2020-02-26 | $20.18M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $17.69M derived: sum of 2 quarters · filed 2020-02-26 | $17.11M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $20.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $20.01M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$585.00K 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $24.59M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |